Transcranial Magnetic Stimulation (TMS) is an increasingly popular treatment option for patients with major depression disorder (MDD) and obsessive-compulsive disorder (OCD). It has been approved by the FDA since 2009, is CE certified for clinical use in the EU, and is reimbursed by health care insurers. Still, there are many different ways of placing the TMS coil over the target brain area.
During this webinar, Nickolay Smirnov, Neurosoft Chief Commercial Officer, will present the history of TMS, after which Martijn Arns, Brainclinis Foundation Research Director, will give a keynote lecture regarding a relatively new technique for placing the TMS coil over a target brain region: neuro-cardiac-guided TMS. This method employs heart rate assessed during TMS stimulation to verify 'target engagement' of the Frontal-Vagal network, which is hypothesized to be involved in depression. Two experts in the field of TMS and neuro-cardiac-guided TMS will guide you through the latest advancements and will share their insights. There will be ample room to ask questions.
The webinar will take place using the Zoom platform, with a maximum of 100 participants that have registered upfront. You can register here using the online form from the Zoom platform. A few days before the webinar, you will receive the Zoom link to participate by email. Participation is free for everyone.
